Original article| Volume 44, 102336, September 2020

Metabolic syndrome components and disease disability in egyptian multiple sclerosis patients


      • There is high frequency of MetS and its component in Egyptian MS patients.
      • Metabolic syndrome was not a significant factor affecting disability in MS patients.
      • Disease duration, current medication, BMI and dyslipidemia were the independent factors significantly associated with disability in MS patients.



      There is limited and inconsistent data on metabolic syndrome (MetS) in multiple sclerosis (MS) patients. The aim of this study was to estimate the frequency of MetS and its components in MS patients and to evaluate their association with disease disability in Egyptian MS patients.


      A cross-section study was carried out on 60 patients (19 males and 41 females) with relapsing remitting MS. All patients were subjected to full general and neurological examination, laboratory and radiological investigations. Assessment of disease disability was performed using Expanded Disability Status Scale (EDSS) and MetS was diagnosed according to National Cholesterol Education Program Adult Treatment Panel Ш (NCEP-ATP III).


      The frequency of MetS in MS patients was 36.7%. Our findings show that 53.3% of MS patients had abdominal obesity, 21.7% had hypertension, 38.3% had diabetes mellitus, 43.3% had elevated triglycerides level and 56.7% had dyslipidemia. Linear regression analysis revealed that body mass index (BMI), dyslipidemia, current medication and disease duration were significantly associated with disease disability.


      High frequency of MetS and its component was observed in MS patients. Disease duration and current medication as well as some MetS component such as BMI, dyslipidemia, were significantly associated with disability in MS patients.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Multiple Sclerosis and Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Palavra F.
        • Almeida L.
        • Ambrósio A.F.
        • et al.
        Obesity and brain inflammation: a focus on multiple sclerosis.
        Obesity Reviews. 2016; 17: 211-224
        • Kassi E.
        • Pervanidou P.
        • Kaltsas G.
        • et al.
        Metabolic syndrome; definitions and controversies.
        BMC Med. 2011; 9: 48
        • Versini M.
        • Jeandel P.Y.
        • Rosenthal E.
        • et al.
        Obesity in autoimmune diseases: not a passive bystander.
        Autoimmun Rev. 2014; 13: 981-1000
        • Munger K.L.
        • Chitnis T.
        • Ascherio A
        Body size and risk of MS in two cohorts of US women.
        Neurology. 2009; 73: 1543-1550
        • Polman C.H.
        • Reingold S.C.
        • Banwell B.
        • et al.
        Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria.
        Ann. Neurol. 2011; 69: 292-302
        • Thompson A.J.
        • Banwell B.L.
        • Barkhof F.
        • et al.
        Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.
        Lancet Neurol. 2018; 17: 162-173
        • Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP)
        Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).
        JAMA. 2001; 285: 2486-2497
        • Sicras-Mainar A.
        • Ruíz-Beato E.
        • Navarro-Artieda R.
        • et al.
        Comorbidity and metabolic syndrome in patients with multiple sclerosis from Asturias and Catalonia, Spain.
        BMC Neurol. 2017; 17: 134
        • Kurtzke J.F.
        Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).
        Neurology. 1983; 33: 1444-1452
        • Conradsson D.
        • Ytterberg C.
        • von Koch L.
        • et al.
        Changes in disability in people with multiple sclerosis: a 10-year prospective study.
        J. Neurol. 2018; 265: 119-126
        • IBM Corp
        IBM SPSS Statistics for Windows, Version 20.
        IBM Corp, Armonk, NY2010
        • Pinhas-Hamiel O.
        • Livne M.
        • Harari G.
        • et al.
        Prevalence of overweight, obesity and metabolic syndrome components in multiple sclerosis patients with significant disability.
        Eur. J. Neurol. 2015; 22: 1275-1279
        • Morales I.B.
        • Saipetch C.
        • Turetsky A.
        • et al.
        Metabolic Syndrome and Disability in Multiple Sclerosis: a Retrospective Study.
        Neurology. 2014; 82 (168): P6
        • Soliman R.H.
        • Farhan H.M.
        • Hegazy M.
        • et al.
        Impact of insulin resistance and metabolic syndrome on disability in patients with multiple sclerosis.
        Egypt J. Neurol. Psychiatry Neurosurg. 2020; 56: 18
        • Abd ELSayed M.M.
        • Zaki M.A.
        • Abd ElSamie M.M
        The Metabolic Syndrome in Multiple Sclerosis Patients.
        N. Y. Sci. J. 2020; 13: 40-47
        • Weinstock-Guttman B.
        • Zivadinov R.
        • Mahfooz N.
        • et al.
        Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis.
        J. Neuroinflammation. 2011; 8: 127
        • Tettey P.
        • Van Der Mei I.A.F
        Lipids in multiple sclerosis: adverse lipid profiles, disability and disease progression.
        Clin. Lipidol. 2014; 9: 473-475
        • Hou W.H.
        • Li C.Y.
        • Chang H.
        • et al.
        A population based cohort study suggests an increased risk of multiple sclerosis incidence in patients with type 2 diabetes mellitus.
        J. Epidemiol. 2017; 27: 235-241
        • Marrie R.A.
        • Yu B.N.
        • Leung S.
        • et al.
        Rising prevalence of vascular comorbidities in multiple sclerosis: validation of administrative definitions for diabetes, hypertension, and hyperlipidemia.
        Mult. Scler. 2012; 18: 1310-1319
        • Villoslada P.
        • Alonso C.
        • Agirrezabal I.
        • et al.
        Metabolomic signatures associated with disease severity in multiple sclerosis.
        Neurol. Neuroimmunol Neuroinflamm. 2017; 4: e321
        • Hubbard E.A.
        • Motl R.W.
        • Bo Fernhall
        Sedentary Behavior and Blood Pressure in Patients with Multiple Sclerosis.
        Int. J. MS Care. 2018; 20: 1-8
        • Zamzam D.
        • FoadM Swelam M
        • et al.
        Vitamin D and body mass index in Egyptian multiple sclerosis patients.
        Mult Scler Relat Dis. 2019; 28: 313-316
        • Fisniku L.K.
        • Brex P.A.
        • Altmann D.R.
        • et al.
        Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis.
        Brain. 2008; 131: 808-817
        • Minneboo A.
        • Barkhof F.
        • Polman C.H.
        • et al.
        Infratentorial Lesions Predict Long-term Disability in Patients with Initial Findings Suggestive of Multiple Sclerosis.
        Arch. Neurol. 2004; 61: 217-221
        • Kvistad S.S.
        • Myhr K.M.
        • Holmoy T.
        • et al.
        Body mass index influence interferon-beta treatment response inmultiple sclerosis.
        J. Neuroimmunol. 2015; 288: 92-97
        • Briggs F.B.S.
        • Thompson N.R.
        • Conway D.S
        Prognostic factors of disability in relapsing remitting multiple sclerosis.
        Mult Scler Relat Dis. 2019; 30: 9-16
        • Conway D.S.
        • Thompson N.R.
        • Cohen J.A
        Influence of hypertension, diabetes, hyperlipidemia, and obstructive lung disease on multiple sclerosis disease course.
        Mult Scler. 2017; 23: 277-285
        • Weinstock-Guttman B.
        • Zivadinov R.
        • Horakova D.
        • et al.
        Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event.
        J Neurol Neurosur Ps. 2013; 84: 1186-1191
        • Browne R.W.
        • Weinstock-Guttman B.
        • Horakova D.
        • et al.
        Apolipoproteins are associated with new MRI lesions and deep grey matter atrophy in clinically isolated syndromes.
        J neurol neurosurg psychiatry. 2014; 85: 859-864
        • Tettey P.
        • Siejka D.
        • Simpson S.
        • et al.
        Frequency of comorbidities and their association with clinical disability and relapse in multiple sclerosis.
        Neuroepidemiology. 2016; 46: 106-113
        • Hedstrom A.K.
        • Lima Bomfim I.
        • Barcellos L.
        • et al.
        Interaction between adolescent obesity and HLA risk genes in the etiology of multiple sclerosis.
        Neurology. 2014; 82: 865-872
        • Roytblat L.
        • Rachinsky M.
        • Fisher A.
        • et al.
        Raised interleukin-6 levels in obese patients.
        Obes. Res. 2000; 8: 673-675
        • Langer-Gould A.
        • Brara S.M.
        • Beaber B.E.
        • et al.
        Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome.
        Neurology. 2013; 80: 548-552
        • Mowry E.M.
        • Azevedo C.J.
        • McCulloch C.E.
        • et al.
        Body mass index, but not vitamin D status, is associated with brain volume change in MS.
        Neurology. 2018; 91: e2256-e2264
        • Manouchehrinia A.
        • Hedstrom A.K.
        • Alfredsson L.
        • et al.
        Association of pre-disease body mass index with multiple sclerosis prognosis.
        Front Neurol. 2018; 9: 232